Merck (NYSE:MRK) reported positive Phase 3 results for tulisokibart, an anti-TL1A monoclonal antibody in moderate-to-severe ...

Researchers at Peter MacCallum Cancer Centre have developed a digital phenotype to assist with automatically identifying ...

Once regarded as a disease affecting people over the age of 50, colorectal cancer is now rising at an alarming rate among ...

AbbVie today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 ...

Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score = 20 and key ...

A quiet layer of biology is beginning to change how health is understood, and it sits on the surface of nearly every cell in ...

Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI. You are ...

By Puyaan Singh June 29 (Reuters) - Abivax said on Monday its experimental ulcerative colitis drug helped harder-to-treat groups of patients achieve remission, sending U.S.-listed shares of the ...

Safety concerns tied to Abivax's experimental bowel disease drug tanked company shares just weeks ago. But a new analysis ...

DRB1*01:03 allele was associated with severe outcomes across inflammatory bowel disease subtypes, including perianal complications, advanced therapy use and surgical interventions, according to study ...